Elranatamab in R/R Multiple Myeloma

NCT06138275 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Refractory Multiple Myeloma
Relapse Multiple Myeloma
Multiple Myeloma

Interventions

DRUG: Elranatamab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]